Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2013

View Archived Issues

Molecular InSight Pharmaceuticals prepares novel rhenium complexes

U.S. team discovers new monoacylglycerol lipase inhibitors

Reversal of apixaban anticoagulation with PRT-064445 in phase II study detailed

Transition Therapeutics licenses candidate for osteoarthritis pain from Lilly

Enrollment begins in phase II LGX-818 melanoma trial

FDA approves use of Hologic's Aptima HPV assay on fully automated Panther system

New Alzheimer's disease model is based on N-truncated Abeta4-42 expression

FDA accepts for review Merck & Co.'s vorapaxar NDA for secondary complications

Sarepta plans eteplirsen NDA submission

NOXXON's phase IIa study in diabetic nephropathy now fully enrolled

Reversal of oral anticoagulant activity with PER-977 described

Galectin begins dosing in phase I trial of GR-MD-02

Questcor to commence screening for phase II study of H.P. Acthar Gel in ALS

FDA grants orphan drug designation to Verastem's defactinib in mesothelioma

Fred Hutchinson Cancer Research Center receives National Cancer Institute grant

FDA advisory committee votes in favor of Cimzia for active axial spondyloarthritis

Northeastern University discloses new CB1 receptor modulators

Valproic acid analogue evaluated for antimigraine potential

InhibOx receives grant to develop novel therapies for multidrug-resistant infections

Allergan prepares new sodium channel blockers

Researchers at Complix patent novel polypeptides for cancer

Health Canada approves two GSK drugs for metastatic melanoma

Akebia Therapeutics commences phase IIb trial of oral HIF-PH inhibitor for anemia

New agents for tuberculosis synthesized by CSIR

Scientists at BioAlliance divulge new murine/human antibodies targeting TfR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...